Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice

Journal of Lipid Research

Volumn 57, Issue 8, 2016, Pages 1455-1464

  Schonewille, Marleen ^a   De Boer, Jan Freark ^b   Mele, Laura ^a   Wolters, Henk ^a   Bloks, Vincent W ^a   Wolters, Justina C ^b   Kuivenhoven, Jan A ^b   Tietge, Uwe J F ^a   Brufau, Gemma ^a   Groen, Albert K ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biliary cholesterol; Biosynthesis; Cholesterol; Intestine; Liver; Supplementary cholesterol absorption; Transintestinal cholesterol excretion

Indexed keywords

ABC TRANSPORTER G5; ABC TRANSPORTER G8; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ROSUVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; GLUTARIC ACID DERIVATIVE;

ABCG5 GENE; ABCG8 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYP7A1 GENE; CYP8B1 GENE; DRUG MECHANISM; FECES ANALYSIS; GENE; GENE EXPRESSION; INTESTINAL EXCRETION; LDLR GENE; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SREBP2 GENE; WEIGHT CHANGE; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; LIVER; METABOLISM; PRECLINICAL STUDY; SMALL INTESTINE;

ANIMALS; CHOLESTEROL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GLUTARATES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ELIMINATION; INTESTINE, SMALL; LIVER; LOVASTATIN; MALE; MICE, INBRED C57BL;

EID: 84980009636     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M067488     Document Type: Article

References (55)

1. McKenney, J. M. 2003. Pharmacologic characteristics of statins. Clin. Cardiol. 26 (Suppl. 3): 32-38.
2. Schachter, M. 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19: 117-125.
3. Vaughan, C. J., and A. M. Gotto, Jr. 2004. Update on statins: 2003. Circulation. 110: 886-892.
4. Istvan, E. S. 2002. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am. Heart J. 144 (Suppl.): S27-S32.
5. Nohturfft, A., R. A. DeBose-Boyd, S. Scheek, J. L. Goldstein, and M. S. Brown. 1999. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc. Natl. Acad. Sci. USA. 96: 11235-11240.
6. Sakai, J., and R. B. Rawson. 2001. The sterol regulatory element-binding protein pathway: control of lipid homeostasis through regulated intracellular transport. Curr. Opin. Lipidol. 12: 261-266.
7. Brown, M. S., and J. L. Goldstein. 1999. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA. 96: 11041-11048.
8. Smith, J. R., T. F. Osborne, J. L. Goldstein, and M. S. Brown. 1990. Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J. Biol. Chem. 265: 2306-2310.
9. Briggs, M. R., C. Yokoyama, X. Wang, M. S. Brown, and J. L. Goldstein. 1993. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. J. Biol. Chem. 268: 14490-14496.
10. Wang, X., M. R. Briggs, X. Hua, C. Yokoyama, J. L. Goldstein, and M. S. Brown. 1993. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization. J. Biol. Chem. 268: 14497-14504.
11. Naoumova, R. P., A. D. Marais, J. Mountney, J. C. Firth, N. B. Rendell, G. W. Taylor, and G. R. Thompson. 1996. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis. 119: 203-213.
12. Miettinen, T. A., and H. Gylling. 2003. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest. 33: 976-982.
13. Vanhanen, H., Y. A. Kesaniemi, and T. A. Miettinen. 1992. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism. 41: 588-595.
14. Vanhanen, H. T., and T. A. Miettinen. 1995. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis. 115: 135-146.
15. Gylling, H., and T. A. Miettinen. 1996. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J. Lipid Res. 37: 1776-1785.
16. Goldberg, I. J., S. Holleran, R. Ramakrishnan, M. Adams, R. H. Palmer, R. B. Dell, and D. S. Goodman. 1990. Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. J. Clin. Invest. 86: 801-808.
17. Kallien, G., K. Lange, E. F. Stange, and J. Scheibner. 1999. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology. 30: 14-20.
18. Morand, O. H., J. D. Aebi, H. Dehmlow, Y. H. Ji, N. Gains, H. Lengsfeld, and J. Himber. 1997. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J. Lipid Res. 38: 373-390.
19. Bergstrom, J. D., R. G. Bostedor, D. J. Rew, W. M. Geissler, S. D. Wright, and Y. S. Chao. 1998. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim. Biophys. Acta. 1389: 213-221.
20. Fujioka, T., F. Nara, Y. Tsujita, J. Fukushige, M. Fukami, and M. Kuroda. 1995. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim. Biophys. Acta. 1254: 7-12.
21. Roglans, N., J. C. Verd, C. Peris, M. Alegret, M. Vazquez, T. Adzet, C. Diaz, G. Hernandez, J. C. Laguna, and R. M. Sanchez. 2002. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids. 37: 445-454.
22. Verd, J. C., C. Peris, M. Alegret, C. Diaz, G. Hernandez, M. Vazquez, T. Adzet, J. C. Laguna, and R. M. Sanchez. 1999. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br. J. Pharmacol. 127: 1479-1485.
23. Yamauchi, S., W. G. Linscheer, and D. H. Beach. 1991. Increase in serum and bile cholesterol and HMG-CoA reductase by lovastatin in rats. Am. J. Physiol. 260: G625-G630.
24. Reihnér, E., M. Rudling, D. Stahlberg, L. Berglund, S. Ewerth, I. Björkhem, K. Einarsson, and B. Angelin. 1990. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323: 224-228.
25. Gazzerro, P., M. C. Proto, G. Gangemi, A. M. Malfitano, E. Ciaglia, S. Pisanti, A. Santoro, C. Laezza, and M. Bifulco. 2012. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64: 102-146.
26. Pasha, M. K., S. Muzeeb, S. J. Basha, D. Shashikumar, R. Mullangi, and N. R. Srinivas. 2006. Analysis of five HMG-CoA reductase inhibitors-atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomed. Chromatogr. 20: 282-293.
27. Neto-Ferreira, R., V. N. Rocha, V. Souza-Mello, C. A. Mandarimde-Lacerda, and J. J. de Carvalho. 2013. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol. Metab. Syndr. 5: 32.
28. Marchesi, M., C. Parolini, S. Caligari, D. Gilio, S. Manzini, M. Busnelli, P. Cinquanta, M. Camera, M. Brambilla, C. R. Sirtori, et al. 2011. Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL. Br. J. Pharmacol. 164: 1460-1468.
29. Parker, R. A., R. Garcia, C. S. Ryan, X. Liu, P. Shipkova, V. Livanov, P. Patel, and S. P. Ho. 2013. Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. J. Lipid Res. 54: 2400-2409.
30. Le May, C., J. M. Berger, A. Lespine, B. Pillot, X. Prieur, E. Letessier, M. M. Hussain, X. Collet, B. Cariou, and P. Costet. 2013. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33: 1484-1493.
31. Brufau, G., and A. K. Groen. 2011. Characterization of whole body cholesterol fluxes in the mouse. Curr. Protoc. Mouse Biol. 1: 413-427.
32. Previs, S. F., A. Mahsut, A. Kulick, K. Dunn, G. Andrews-Kelly, C. Johnson, G. Bhat, K. Herath, P. L. Miller, S. P. Wang, et al. 2011. Quantifying cholesterol synthesis in vivo using (2)H(2)O: enabling back-to-back studies in the same subject. J. Lipid Res. 52: 1420-1428.
33. van der Veen, J. N., T. H. van Dijk, C. L. Vrins, H. van Meer, R. Havinga, K. Bijsterveld, U. J. Tietge, A. K. Groen, and F. Kuipers. 2009. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284: 19211-19219.
34. Out, C., J. V. Patankar, M. Doktorova, M. Boesjes, T. Bos, S. de Boer, R. Havinga, H. Wolters, R. Boverhof, T. H. van Dijk, et al. 2015. Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4. J. Hepatol. 63: 697-704.
35. Neese, R. A., D. Faix, C. Kletke, K. Wu, A. C. Wang, C. H. Shackleton, and M. K. Hellerstein. 1993. Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA. Am. J. Physiol. 264: E136-E147.
36. Lee, W. N., L. O. Byerley, E. A. Bergner, and J. Edmond. 1991. Mass isotopomer analysis: theoretical and practical considerations. Biol. Mass Spectrom. 20: 451-458.
37. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
38. Voshol, P. J., R. Havinga, H. Wolters, R. Ottenhoff, H. M. Princen, R. P. Oude Elferink, A. K. Groen, and F. Kuipers. 1998. Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology. 114: 1024-1034.
39. MacLean, B., D. M. Tomazela, N. Shulman, M. Chambers, G. L. Finney, B. Frewen, R. Kern, D. L. Tabb, D. C. Liebler, and M. J. MacCoss. 2010. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 26: 966-968.
40. Gates, S. C., and C. C. Sweeley. 1978. Quantitative metabolic profiling based on gas chromatography. Clin. Chem. 24: 1663-1673.
41. Windler, E., B. C. Zyriax, F. Kuipers, J. Linseisen, and H. Boeing. 2009. Association of plasma phytosterol concentrations with incident coronary heart disease: data from the CORA study, a casecontrol study of coronary artery disease in women. Atherosclerosis. 203: 284-290.
42. Plösch, T., V. W. Bloks, J. F. Baller, R. Havinga, H. J. Verkade, P. L. Jansen, and F. Kuipers. 2002. Mdr P-glycoproteins are not essential for biliary excretion of the hydrophobic heme precursor protoporphyrin in a griseofulvin-induced mouse model of erythropoietic protoporphyria. Hepatology. 35: 299-306.
43. Stricker, D. 2008. BrightStat.com: free statistics online. Comput. Methods Programs Biomed. 92: 135-143.
44. Andersen, J. M., and J. M. Dietschy. 1979. Absolute rates of cholesterol synthesis in extrahepatic tissues measured with 3H-labeled water and 14C-labeled substrates. J. Lipid Res. 20: 740-752.
45. Horton, J. D., N. A. Shah, J. A. Warrington, N. N. Anderson, S. W. Park, M. S. Brown, and J. L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA. 100: 12027-12032.
46. Brufau, G., A. K. Groen, and F. Kuipers. 2011. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler. Thromb. Vasc. Biol. 31: 1726-1733.
47. Cholesterol Treatment Trialists' (CTT) Collaboration. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376: 1670-1681.
48. Funatsu, T., K. Suzuki, M. Goto, Y. Arai, H. Kakuta, H. Tanaka, S. Yasuda, M. Ida, S. Nishijima, and K. Miyata. 2001. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 157: 107-115.
49. Bilhartz, L. E., D. K. Spady, and J. M. Dietschy. 1989. Inappropriate hepatic cholesterol synthesis expands the cellular pool of sterol available for recruitment by bile acids in the rat. J. Clin. Invest. 84: 1181-1187.
50. Edwards, P. A., H. Muroya, and R. G. Gould. 1972. In Vivo demonstration of the circadian rhythm of cholesterol biosynthesis in the liver and intestine of the rat. J. Lipid Res. 13: 396-401.
51. Chuang, J. C., M. A. Valasek, A. M. Lopez, K. S. Posey, J. J. Repa, and S. D. Turley. 2014. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. Biochem. Pharmacol. 88: 351-363.
52. Freeman, M. L., W. F. Prigge, D. B. Hunninghake, W. C. Duane, and R. L. Gebhard. 1988. Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy. J. Lipid Res. 29: 839-845.
53. Linscheer, W. G., B. Atreyee, K. M. Uma, W. John, N. Sandor, and N. Jyotirmoy. 1995. Lovastatin induces synthesis of cholesterol, which acts as a secretagogue of biliary phospholipids in rats. Am. J. Physiol. 268: G242-G250.
54. Hanson, D. S., and W. C. Duane. 1994. Effects of lovastatin and chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects. J. Lipid Res. 35: 1462-1468.
55. Bodmer, M., Y. B. Brauchli, S. Krahenbuhl, S. S. Jick, and C. R. Meier. 2009. Statin use and risk of gallstone disease followed by cholecystectomy. J. Am. Med. Assoc. 302: 2001-2007.